Skip to main content

Table 2 Comparison of CSF analysis and LCT measurements between AD and healthy groups

From: Increased CSF tau level is correlated with decreased lamina cribrosa thickness

  AD group (n = 18) Healthy group (n = 26) P value
CSF analysis
 CSF pressure (mmHg)a 12.8 ± 2.6 14.4 ± 2.5 0.062
 Aβ1–42 (pg/ml)a 306.52 ± 116.21 463.46 ± 124.69 <0.001
 T-tau (pg/ml)b 110.04 ± 57.08 62.51 ± 19.73 <0.001
 P-tau181P (pg/ml)b 51.66 ± 19.40 28.07 ± 14.14 <0.001
LCT measurements
 Superior LCT (μm)a 227.61 ± 42.07 238.81 ± 42.08 0.390
 Central LCT (μm)a 267.72 ± 31.35 262.65 ± 49.05 0.701
 Inferior LCT (μm)b 232.00 ± 45.67 242.27 ± 46.60 0.423
 Average LCT (μm)a 242.46 ± 31.93 247.95 ± 37.55 0.616
  1. Data are presented as the mean ± standard deviation, unless otherwise specified. Statistically significant values are shown in bold
  2. aComparisons were made using an independent-samples t test
  3. bComparisons were made using a Mann–Whitney U test
  4. 1–42 amyloid β1–42, AD Alzheimer’s disease, CSF cerebrospinal fluid, LCT lamina cribrosa thickness, P-tau 181P , phosphorylated tau181P, T-tau total tau